{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:15:43Z","timestamp":1788909343465,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["152001014"],"award-info":[{"award-number":["152001014"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer BV"},{"name":"Roche Nederland BV"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11136-017-1704-4","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T12:10:43Z","timestamp":1505477443000},"page":"115-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"27","author":[{"given":"S.","family":"de Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Versteegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A. L. M.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"issue":"4","key":"1704_CR1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","volume":"60","author":"B Ljungberg","year":"2011","unstructured":"Ljungberg, B., Campbell, S. C., Choi, H. Y., Jacqmin, D., Lee, J. E., Weikert, S., et al. (2011). The epidemiology of renal cell carcinoma. European Urology, 60(4), 615\u2013621.","journal-title":"European Urology"},{"issue":"2","key":"1704_CR2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., et al. (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. The Lancet Oncology, 14(2), 141\u2013148.","journal-title":"The Lancet Oncology"},{"issue":"Suppl 1","key":"1704_CR3","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10555-012-9357-9","volume":"31","author":"J Lambea","year":"2012","unstructured":"Lambea, J., Hinojo, C., Lainez, N., Lazaro, M., Leon, L., Rodriguez, A., et al. (2012). Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer Metastasis Reviews, 31(Suppl 1), S33\u2013S39.","journal-title":"Cancer Metastasis Reviews"},{"issue":"2","key":"1704_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356(2), 115\u2013124.","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"1704_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine, 356(2), 125\u2013134.","journal-title":"The New England Journal of Medicine"},{"issue":"22","key":"1704_CR6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine, 356(22), 2271\u20132281.","journal-title":"The New England Journal of Medicine"},{"issue":"9605","key":"1704_CR7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet, 370(9605), 2103\u20132111.","journal-title":"Lancet"},{"issue":"33","key":"1704_CR8","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S. S., et al. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(33), 5422\u20135428.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"9637","key":"1704_CR9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet, 372(9637), 449\u2013456.","journal-title":"Lancet"},{"issue":"6","key":"1704_CR10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(6), 1061\u20131068.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"9807","key":"1704_CR11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet (London, England), 378(9807), 1931\u20131939.","journal-title":"Lancet (London, England)"},{"issue":"Suppl 2","key":"1704_CR12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3747\/co.v18is2.958","volume":"18","author":"SJ Hotte","year":"2011","unstructured":"Hotte, S. J., Bjarnason, G. A., Heng, D. Y., Jewett, M. A., Kapoor, A., Kollmannsberger, C., et al. (2011). Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Current Oncology (Toronto, Ont.), 18(Suppl 2), S11\u2013S19.","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"1704_CR13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12885-016-2395-x","volume":"16","author":"S Groot De","year":"2016","unstructured":"De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B., Kiemeney, L. A., et al. (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC Cancer, 16, 364.","journal-title":"BMC Cancer"},{"issue":"5","key":"1704_CR14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"key":"1704_CR15","volume-title":"EQ-5D value sets: Inventory, comparative review and user guide","year":"2007","unstructured":"Szende, A., Oppe, M., & Devlin, N. (Eds.). (2007). EQ-5D value sets: Inventory, comparative review and user guide (1st\u00a0edn.). Dordrecht: Springer.","edition":"1"},{"issue":"1","key":"1704_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002). Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20(1), 289\u2013296.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"1704_CR17","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., et al. (2001). The EORTC QLQ-C30 scoring manual (3rd\u00a0edn.). New York: Wiley.","edition":"3"},{"issue":"4","key":"1704_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh, M. M., Vermeulen, K. M., Evers, S. M., de Wit, G. A., Prenger, R., & Stolk, E. A. (2016). Dutch tariff for the five-level version of EQ-5D. Value in Health, 19(4), 343\u2013352.","journal-title":"Value in Health"},{"key":"1704_CR19","volume-title":"Longitudinal data analysis","author":"D Hedeker","year":"2006","unstructured":"Hedeker, D., & Gibbons, R. D. (2006). Longitudinal data analysis. New York: Wiley."},{"issue":"4","key":"1704_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White, I. R., Royston, P., & Wood, A. M. (2011). Multiple imputation using chained equations: Issues and guidance for practice. Statistics in Medicine, 30(4), 377\u2013399.","journal-title":"Statistics in Medicine"},{"issue":"1","key":"1704_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273(1), 59\u201365.","journal-title":"JAMA"},{"issue":"Suppl 3","key":"1704_CR22","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., et al. (2014). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO, 25(Suppl 3), iii49\u2013iii56.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"4","key":"1704_CR23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","volume":"102","author":"D Cella","year":"2010","unstructured":"Cella, D., Michaelson, M. D., Bushmakin, A. G., Cappelleri, J. C., Charbonneau, C., Kim, S. T., et al. (2010). Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: Final results and geographical analysis. British Journal of Cancer, 102(4), 658\u2013664.","journal-title":"British Journal of Cancer"},{"issue":"2","key":"1704_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14020","volume":"14","author":"J Thompson Coon","year":"2010","unstructured":"Thompson Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T., et al. (2010). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation. Health Technology Assessment, 14(2), 1\u2013184.","journal-title":"Health Technology Assessment"},{"issue":"24","key":"1704_CR25","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1200\/JCO.2007.13.2662","volume":"26","author":"E Remak","year":"2008","unstructured":"Remak, E., Charbonneau, C., Negrier, S., Kim, S. T., & Motzer, R. J. (2008). Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology: Official Journal Of The American Society of Clinical Oncology, 26(24), 3995\u20134000.","journal-title":"Journal of Clinical Oncology: Official Journal Of The American Society of Clinical Oncology"},{"issue":"1","key":"1704_CR26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24(1), 16\u201324.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"8","key":"1704_CR27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., et al. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England Journal of Medicine, 369(8), 722\u2013731.","journal-title":"The New England Journal of Medicine"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-017-1704-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-017-1704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-017-1704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T22:53:48Z","timestamp":1693004028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-017-1704-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1007\/s11136-017-1704-4","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]}}}